# Phase II Study of Short-Term Cultured Anti-Tumor Autologous Lymphocytes After Lymphocyte-Depleting Chemotherapy in Metastatic Melanoma

> **NCT00513604** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 158 (actual)

## Conditions studied

- Melanoma
- Malignant Melanoma
- Melanoma, Experimental
- Experimental Melanomas

## Interventions

- **BIOLOGICAL:** aldesleukin
- **BIOLOGICAL:** therapeutic autologous lymphocytes
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine phosphate
- **RADIATION:** Total body irradiation

## Key facts

- **NCT ID:** NCT00513604
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-06
- **Primary completion:** 2012-11
- **Final completion:** 2012-11
- **Target enrollment:** 158 (ACTUAL)
- **Last updated:** 2013-06-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00513604

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00513604, "Phase II Study of Short-Term Cultured Anti-Tumor Autologous Lymphocytes After Lymphocyte-Depleting Chemotherapy in Metastatic Melanoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00513604. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*